CD2, a cell surface glycoprotein expressed on T cells and natural killer cells, can couple to signaling pathways that result in T cell proliferation. An Src-like protein tyrosine kinase, p50 ok, coprecipitates with CD2, and perturbation of CD2 by monoclonal antibodies results in an increase in the activity of p56 kk, suggesting that an interaction with p56 l~k contributes to CD2-mediated signaling. Herein, we investigate the mechanism by which CD2 associates with p561ok. We demonstrate that CD2 and p56 l~k associate when coexpressed in nonlymphoid cells, that this association requires the cytoplasmic domain of CD2, and that the SH3 domain of p561ok mediates its interactions with CD2. Using truncation mutants of CD2, we identify two regions in the cytoplasnfic domain of CD2 involved in binding p56 kk. Each region contains a proline-rich sequence that, in the form of a synthetic peptide, directly binds p56 lck. Thus, proline-rich sequences in the cytoplasmic domain of CD2 allow this transmembrane receptor to bind to the SH3 domain of p561ok.
variety of receptor-ligand interactions occur when T ymphocytes recognize and respond to antigenic peptides bound to MHC molecules on the surfaces of other cells. Although this response depends on the TCR, other cell surface molecules contribute to T cell activation by promoting adhesion to the APC and by providing biochemical signals. CD2, a 55-kD cell surface glycoprotein expressed by T lymphocytes and NK cells, subserves adhesion functions by binding CD48, CD58, and CD59 (1) (2) (3) . It is likely that CD2 also has a role in generating transmembrahe signals during the activation of T cells and NK cells (4, 5) . Perturbation of CD2 can trigger the cytolytic activity of NK cells and can provide a potent stimulus for T cell activation, inducing proliferative responses comparable to those elicited by either mitogenic lectins or mAbs to the TC1K (4, 5) . In several experimental systems, CD2-mediated signaling augments antigen-induced activation of T cells (6, 7) . Moreover, administration ofnondepleting CD2 mAbs to mice induces T cell unresponsiveness, indicating that CD2 either has a critical role in T cell activation in vivo or can deliver signals leading to unresponsiveness (8) . CD2-deficient mice, however, do not manifest an obvious phenotype, suggesting that, ifCD2 does have a critical role in physiological T cell activation, other molecules can assume that role when T lymphocytes develop in the absence of CD2 (9) . Alternatively, the functional deficit resulting from the abscence of CD2 may be subtle. Of interest in this regard, recent data suggest that CD2 plays a unique role in the reversal ofT cell anergy in vitro (10) .
The mechanism by which CD2 couples to signal transduction pathways is uncertain. When T cells are lysed with digitonin or Brij, CD2 coimmunoprecipitates with the TCR (11) (12) (13) (14) . Therefore, like CD4 and CD8, CD2 appears to be in close physical proximity with the TCR (11) (12) (13) (14) . Indeed, CD2-mediated activation requires coexpression of TCR or of receptor complexes, such as CD16, that contain the TCk-{ chain or the closely related Fce receptor ~ chain (15, 16) . Thus, agonist mAbs to CD2 fail to activate T cell lines that express abundant CD2 but that lack TCR (15) . As is the case with the TCP.., appropriate stimulation of CD2 induces tyrosine phosphorylations and polyphosphoinositide turnover (17) (18) (19) (20) . These CD2-induced signaling events depend on the cytoplasmic domain of CD2, which is relatively large (116 amino acids), is highly conserved between human, rat, and mouse, and lacks intrinsic kinase activity (21) (22) (23) (24) .
The remarkable capacity of CD2 to activate T ceils and NK cells raises the possibility that, like the TCR, CD4, and CD8, CD2 interacts with cytoplasmic protein tyrosine kinases (PTK). 1 Several observations support this possibility. Perturbation of CD2 induces protein tyrosine phosphoryla1Abbreviations used in this paper: F.L., full-length; GST, glutathione-S-transferase; PTK, protein tyrosine kinases; S/9, Spodopterafrugiperda. tions, and CD2 signaling requires expression of CD45, a transmembrane tyrosine phosphatase that regulates the activities of Src-like PTK (20, 25) . Stimulation of CD2 on T cells leads to an increase in the specific activity of p56 kk, a lymphoid-specific Src-like PTK (26) . We and others have found that p561Ck as well as p59 fin coimmunoprecipitate with CD2 from detergent lysates of rat T lymphocytes and NK cells, raising the possibility that CD2 associates directly with these Src-like PTK (12, 13, 27) . Herein we examine the mechanism by which CD2 associates with p56 kk.
Materials and Methods
Cell Lines, Cell Culture, mAbs, and Other Reagents. COS 6M cells were grown in DME with 10% FCS. Spodopterafrugiperda (sfg) cells were grown in complete Grace's medium. Anti-rat CD2 mAbs OX-34, OX-54, and OX-55 were the kind gift of A. Williams (Oxford University, Oxford, UK).
Generation of Fusion Proteins and Anti-GST Antiserum. The doning of Wild Type p56 kk into the baculovims shuttle vector pBMS-1 has been previously reported (28) . Domains encompassing the unique regions SH2 and SH3 were cloned in frame with GST into the pGEX-2T vector (Pharmacia, Uppsala, Sweden) by PCR. The unique sequence fusion encompassed amino acids 8-65, whereas the SH3 and SH2 fusions encompassed amino acids 66-113 and 114-235, respectively, of the Wild Type gene. The unique sequence and GST alone were produced with isopropyl-[3-Dthiogalactopyranoside according to the manufacturer's instructions (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) and used for injections in New Zealand white rabbits for polyclonal antisera production. HIS-T7 epitope-tagged fusion proteins were made by cloning the appropriate portions of the rat CD2 cytoplasmic domain in frame into the pet-28 vector (Novagen, Inc., Madison, WI) by PCR. Protein production was induced with IPTG and purified according to the manufacturer's instructions.
Generation ofCD2Mutants. The CD2 truncation mutants were generated by PCP-using the rat cDNA provided by A. Williams. The 5' oligonucleotide located upstream of the CD2 start site contained an EcoRI site and was used for all PCR. Its sequence is 5'-TATATATATAGAATTCCACTGGGA AAAGAA-TGTAAAGATGAGATG-3'. To generate the truncation mutants, we synthesized antisense oligonucleotides containing a stop codon after the appropriate amino acid followed by restriction sites. The sequences for CY6, CY40, CY78, CY85, and CY105 are 5'-TATTTAAGCTTGCGGCCGCTAGTTCCGTTTTTT-CCTCTTCA-3', 5'-TATATATATGAATTCGTCGACCTA-TGATGCTGGTGAGGCCTGGGTTGAGTGTGGCTTGGG-3', 5'-TATATAATAGTCGACGCGGCCGCCTATCTCTTC-TTCGGCTGGTGCTCACG-3', 5'-TATAATATAGTCGAC-GCGGCCGCTACTGTGTGCCTGATGGAGGAGGTCTC-3', and 5'-TATATATATGAATTCGTCGACCTAACAGGGAGG-CTTTGGCTGAACTCGGGGTCTGGGCAAAGG-3', respectively. The PCR products were cloned into pSM for expression in COS cells and pVL1393 for recombination with BaculoGold DNA and expression in Sf9 cells (PharMingen, San Diego, CA). The internal deletion designated CY49.69 (lacking amino acids 49-69 of the cytoplasmic tail of rat CD2) was generated by overlap PCR as described (29) . 5' and 3' overlapping PCR fragments were generated for the internal deletion. Oligonuceotides used for the PCR reactions were as follows: 5' fragment of CY49.69, 5'-TATATATATAGAATTCCACTGGGAAAAGAATGTAAA-GATGAGATG-3' and 5'-CTTCGGCTGGTGCTCACGGTT-AGCTTGGGAAGCCACTGGATT-3'; and the 3' fragment of CY49.69, 5'-AATCCAGTGGCTTCCCAAGCTAACCGTGAG-CACCAGCCGAAG-3' and 5'-TATAAAGTCGACGCGGCC-GCTTAATTAGGGGGTGGCAACGAAAC-3'. The internal deletion designated CY7.4l (lacking amino acids 7-41 of the cytoplasmic tail of rat CD2) was also generated by overlap PCR using the following primers: 5' fragment of CY7.41, 5'-TATATAGAA-TTCCACTGGGAAAAGAATGTAAAGATGAGATG-3' and 5'-GTGCTCACGGTTGCCAGGTGTCTGGAGATG-3'; and the 3' fragment of CY7.4l, 5'-CAGACACCTGGCAACCGTGAG-CACCAGCCG-3' and 5'-TATAAAGTCGACGCGGCCGCT-TAATTAGGGGGTGGCAACGAAAC-3'. The DNA sequence of the cytoplasmic domain of each mutant was verified.
Expression of Full-Length and Mutant CD2 and p5~ "k in COS Cells and Sf9 Cells. The various CD2 constructs and p56 lck were expressed in COS cells by transient transfection using DEAE dextran (Sigma Chemical Co., St. Louis, MO) according to published methods (30) . To express the constructs in Sf9 cells, we transfected the various constructs into Sf9 cells in the presence of BaculoGold DNA (PharMingen) according to the manufacturer's instructions, harvested, and amplified the recombinant baculovirus. The virus was then used for large-scale preparations of recombinant protein.
Immunoprecipitations, In Vitro Kinase Assays, and Immunoblotring. Anti-CD2 immunoprecipitations were performed using either mAb OX-34 (mouse IgG2b) coupled to Pansorbin cells (Calbiochem Corp., LaJolla, CA), or mAb OX-55 (mouse IgG1) coupled either to Pansorbin cells coated with rabbit anti-mouse Ig antiserum (Cappel Laboratories, Malverne, PA) or to Sepharose-coupled goat anti-mouse Ig (Cappel Laboratories). In vitro kinase assays were performed as described (27) . Anti-GST immunoblots were performed by blocking the gel transferred to Immobilon-P (Millipore Corp., Bedford, MA) in 20 mM Tris, pH 8, 150 mM NaC1, 0.05% Tween 20 (TBST) with 3% nonfat dried milk for 30 min followed by incubation with anti-GST antiserum (1:500 in TBST with 3% milk) for 2 h at room temperature. The blots were washed three times for 5 rain in TBST and incubated with 12SI-labeled protein A (Amersham Corp., Arlington Heights, IL) at 0.5 mCi/rnl in TBST with 3% milk for 1 h at room temperature. The blots were washed three times for 5 rain in TBST, dried, and evaluated by autoradiography. Anti-rat CD2 immunoblots were performed as above using mAb OX-34 at 0.1 Izg/ml in TBST with 3% milk, and anti-T7 immunoblots were performed using anti-T7 mAb (Novagen, Inc.) according to the manufacturer's instructions.
Peptide Generation. The peptides used in these studies were purchased from either Chiron Mimotopes Peptide Systems (San Diego, CA) or Research Genetics (Huntsville, AL), analyzed by mass spectometery or HPLC, and were I>70% pure. The sequences of each peptide are as follows: peptide 1, ASQAPPPPGHH; peptide 2, PGHRPLPPSHR; peptide 3, PKKRPPPSGTQ; peptide 4, GQKGPPLPIq.PRV; and peptide 5, RVQPKPPCGSG. (Peptide 4 is a 12-met; a glycine was added to the NH 2 terminus to prevent cyclization of the NH2-terminal glutamine.) Equivalent molar quantities of the peptides were conjugated to activated CH Sepharose 4B (Pharmacia LKB Biotechnology Inc.) per the manufacturer's instructions and were used to precipitate purified GST/p561ok.
Determination of Ca 2 § Fluorescence and IL-2 Production. Jurkat cells were loaded with the Ca2+-sensitive fluor and lndo-1, and calcium fluorescence was monitored as previously described (31) . To determine IL-2 production, we cultured Jurkat cells at 1() ~ cells/ml in 96-well plates and stimulated the cells for 18 h with Figure 1 . Protein kinase activity coprecipitates with CD2 from rat T cells. Freshly isolated rat splenic T cells were lysed in a buffer containing 1% NP-40, and 500 lig of the precleared lysate was subjected to immunoprecipitation with antibodies directed against either CD2 (OX-34), CD4 (W3-25), or CD8 (OX-8) as indicated. The immune complexes were washed and incubated in a kinase reaction buffer containing 10 p, Ci of [~/-32p]ATP as previously described (27) . Phosphoproteins were separated by SDS-PAGE on an 8% gel, treated with 1 M KOH at 55~ for 1 h, and evaluated by autoradiography. Molecular masses and the location of p56 kk are indicated on the left. media, PMA alone (10 ng/ml), the combination of OX-54 (20 I~g/ml), OX-55 (20 Ixg/ml) and PMA, or the combination of C305 (1:500 dilution from ascites) and PMA. Culture supematants were assayed for IL-2 using a human IL-2 cytoscreen immunoassay kit (Biosource International, Camarillo, CA) according to the manufacturer's instructions.
Results

CD2 and p561ok Associate in Rat T Cells, and This Association Can Be Reproduced in C O S Cells.
As is the case with CD4 and CD8, immunoprecipitates of CD2 from 1% NP-40 lysates of splenic T cells contain a protein kinase activity detected by in vitro kinase assays (Fig. 1 ). We and others have identified p56 kk as one of the PTKs present in these CD2 immunoprecipitates (12, 13, 27) . To determine whether CD2 and p56 lck can associate in a nonlymphoid cell line, we transfected COS cells (a fibroblast line that does not express p56 kk) with cDNAs encoding p56 lck and rat CD2. After 72 h, the cells were solubilized in a buffer containing 1% NP-40, and the resulting lysate was subjected to immunoprecipitation with antibodies directed against CD2 and p56 kk (Fig. 2 A) . An in vitro kinase assay performed on the CD2 immunoprecipitate generated prominent phosphorylated bands that comigrated with autophosphorylated p56 lck. The presence of kinase activity in the CD2 immunoprecipitate required transfection with both the CD2 and p56 lck cDNAs. There was no kinase activity in CD2 immunoprecipitates from COS cells transfected with p56 lck alone, indicating that the CD2 mAb does not cross-react with a PTK. Similarly, in vitro kinase reactions on CD2 immunoprecipitates from COS cells transfected with CD2 alone failed to reveal bands corresponding to Src-family members. Taken together, these results indicate that rat CD2 and p56 Ick associate when coexpressed in COS cells. Comparable results were obtained when human CD2 was coexpressed with p56 lck in COS ceils (data not shown). CD2, therefore, does not require the expression of any other lymphoid specific molecules to associate with p56 lck.
CD2 also binds p56 kk when the latter is in the form of a purified GST fusion protein. After incubating GST/p56 kk with lysate from CD2-expressing COS cells, we i m m u n oprecipitated CD2 and then analyzed the immunoprecipitate for the presence of GST/p56 lck by immunoblotting with an antiserum to GST. As shown in Fig. 2 B, G S T / p56 l~k coprecipitates with CD2. This association requires the presence of the CD2 cytoplasmic domain, as evidenced by the failure to detect G S T / p 5 6 kk in immunoprecipitates of a truncation mutant o f C D 2 (CY6) that lacks all but the first six amino acids of the cytoplasmic domain of CD2.
The SH3 Domain of p56 l"k Mediates Association with CD2.
To determine the region of p561ok that binds to CD2, we constructed GST fusion proteins containing the following domains of p56kk: the NH2-terminal unique region, the SH3 domain, and the SH2 domain (Fig. 3 ). In these experiments, we used Sf9 cells (a blowfly salivary gland cell line) that expressed CD2 after gene transfer. Each of the fusion proteins was incubated with equal aliquots of C D 2 -expressing Sf9 lysate, and then immunoprecipitations with anti-CD2 mAb were performed. The immunoprecipitate was analyzed by inmmnoblotting with anti-GST. The G S T / S H 3 domain fusion protein coprecipitated with CD2, but GST alone, the G S T / u n i q u e region fusion protein, and the G S T / S H 2 domain fusion protein did not (Fig. 4 A) . Next we determined if the G S T / S H 3 domain fusion protein could competitively inhibit the association of CD2 with full-length GST/p56 kk (we used the fusion protein rather than p56 Ick because the fusion protein could be easily purified, permitting better control of its concentration). In each of several experiments, the G S T / S H 3 domain fusion protein, but not G S T / u n i q u e region or GST alone (data not shown), inhibited the binding of CD2 to GST/p561ok (Fig. 4 B) . As was the case with GST/p56 lck, the G S T / S H 3 domain fusion protein associated with full-length (F.L.) Figure 2 . The association of CD2 with p56 kk can be reproduced in nonlymphoid cells and requires the cytoplasmic domain of CD2. (A) p56 lck coprecipitates with rat CD2 when expressed in COS ceils. COS cells were plated onto 100-cm 2 dishes and transfected with 5 ~g of plasrmd DNA encoding the molecules indicated (Tx). After 72 h, the cells were lysed in buffers containing 1% NP-40, and the precleared lysates were subjected to immunoprecipitation with the indicated antibodies (IP). The immune complexes were washed and incubated in a kinase reaction buffer containing 20 p.Ci of ['y-32p]ATP. Phosphoproteins were separated by SDS-PAGE on an 8% gel and evaluated by autoradiography. OX-55 (anti-rat CD2 mAb), OX-8 (isotype-matched control mAb recognizing rat CD8), and crick (rabbit antiserum recognizing p56 kk) were used in the immunoprecipitations. (B) GST/p56 lck fusion protein associates with full-length CD2 (F.L.) but not a tailless CD2 construct (CY6) produced in COS cells. 3 p,g of purified GST/p56 I~k was added to a COS cell lysate containing either F.L. CD2 or a truncation mutant lacking a cytoplasmic domain (CY6). CD2 was immunoprecipated from the lysates, and the CD2 immunoprecipitates were then analyzed by irrmmnoblotting with anti-GST antiserum.
CD2 but not the tailless CY6 mutant of C D 2 (Fig. 4 C) . Similarly, immobilized G S T / S H 3 domain fusion protein precipitated F.L. CD2, but not CY6, from SJ9 lysates (Fig. 4 D) .
The Cytoplasmic Domain of CD2 Directly Associates with p56 tck. T o determine if p56 lck binds directly to the cytoplasmic domain o f CD2, we constructed two nickel histidine T7 epitope-tagged fusion proteins: one of the fulllength cytoplasmic domain o f C D 2 (T7-CY) and one containing the first 40 amino acids of the cytoplasmic domain of C D 2 (T7-40). The fusion proteins were purified to homogeneity, immobilized onto Sepharose with an anti-T7 mAb, and used to affinity precipitate purified G S T / S H 3 fusion protein. T h e G S T / S H 3 fusion coprecipitated with the full-length cytoplasmic domain but not with the fusion protein containing the first 40 amino acids (Fig. 5 A) . Similarly, immobilized G S T / p 5 6 kk fusion protein precipitated T 7 -C Y , but not T 7 -4 0 (Fig. 5 B) . These studies indicate p56 lck binds directly to the cytoplasmic domain of rat C D 2 and that the first 40 amino acids of the cytoplasmic domain of C D 2 are not sufficient for this binding. cytoplasmic domain of C D 2 needed for b i n d i n g to p56 kk, we constructed a series of C D 2 truncations in addition to CY6. Mutants containing 40, 78, 85, and 105 of the 116 amino acids in the cytoplasmic tail of rat C D 2 were generated by PCI< and were designated CY40, CY78, CY85, and CY105, respectively (Fig. 6) .
Identification of the Minimal Cytoplasmic Domain of CD2 Required for Binding top56 Ick. T o determine the minimal
W e expressed F.L. C D 2 and each of the mutants in Sf9 cells and then determined their ability to associate with p56 lck. Lysates from the CD2-expressing Sf9 cells were c o m b i n e d either with wild-type p56 lck produced in Sf9 cells (Fig. 7 A) or with purified GST/p561ok (Fig. 7 B) . F.L. C D 2 and the C D 2 mutants were immunoprecipitated, and the immunoprecipitates were analyzed either by in vitro kinase reaction (Fig. 7 A) or by i m m u n o b l o t t i n g with anti-G S T antiserum (Fig. 7/3 ). In both experiments, equivalent activities or amounts of p561ok coprecipitated with F.L. and CY105 (Fig. 7) . As the cytoplasmic tail of C D 2 was shortened from 105 amino acids to 85 amino acids, there was a decrease in the associated p56 lck to r176 of that seen with F.L. (determined by densitometry of Fig. 7 /3 ). There was no change in the associated p56 lck as the cytoplasmic tail was shortened from 85 to 78 amino acids (Fig. 7 B) . As the T h e data in Fig. 7 are consistent with two possibilities. First, there may be two b i n d i n g sites for p56 kk in CD2: one b e t w e e n a m i n o acids 40 and 78 and another b e t w e e n a m i n o acids 85 and 105. Alternatively, there may be a proximal b i n d i n g site that is secondarily affected by the truncation such that its ability to bind is impaired. T o distinguish b e t w e e n these possibilities, we generated two internal deletion mutants o f CD2: one lacking a m i n o acids 4 9 -6 9 and the other lacking amino acids 7-41 of the cytoplasmic domain (designated CY49.69 and CY7.41, respectively; Fig. 6 ). W e expressed F.L. C D 2 and each o f the internal deletion mutants in SJ9 cells and determined their ability to associate with purified G S T / p 5 6 kk. I m m u n o p r ecipitates of F.L. C D 2 and the C D 2 mutants were analyzed by i m m u n o b l o t t i n g with a n t i -G S T antiserum (Fig. 7 C) . In each of several experiments, CY7.41 consistently b o u n d more G S T / p 5 6 lck than F.L. indicating that the m e m b r a n eproximal portion of the cytoplasmic domain of C D 2 is n o t required for b i n d i n g to p56 kk. CY49.69 b o u n d G S T / p56 kk, b u t not as well as F.L., CD2, consistent with a possible p56 Ick b i n d i n g site b e t w e e n a m i n o acids 40 and 78. T a k e n together with the truncation studies, these data indicate that C D 2 has two discrete regions that bind p56kk: one b e t w e e n amino acids 40 and 78 and the other b e t w e e n amino acids 85 and 105 o f the cytoplasmic tail o f rat CD2. 
Proline-rich Sequences fiom the Cytoplasmk Domain of CD2 Bind p56 tck. Studies by several investigators indicate that the b i n d i n g sites for SH3 domains are rich in proline residues (32-35). T h e cytoplasmic tail of C D 2 has several proline-rich domains. T w o o f these (amino acids 92-95 and
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101-104; Fig. 6 ) lie in the putative binding regions indicated above between amino acids 85 and 105. T w o other proline-rich regions lie between amino acids 49 and 66, the putative binding region deleted in the CY49.69 mutant. A fifth proline-rich sequence (amino acids 79-81) lies in a region whose truncation had no detectable effect on the ability of CD2 to associate with p561ok.
To investigate the possibility that one or more o f the CD2 proline-rich sequences could bind p56 lck, we synthesized 11-mer peptides corresponding to the five proline rich regions between amino acids 49 and 105. The peptides were coupled to activated Sepharose and then incubated in lysis buffer with full-length GST/p56 kk. Eluates from the immobilized peptides were assayed for the presence o f GST/p56 l& by anti-GST immunoblotting. T w o peptides (designated 2 and 4) consistently bound GST/p56 kk (Fig. 8  A) . Peptide 2 corresponds to amino acids 59-69 and thus lies within the putative binding site between amino acids 40 and 78. Peptide 4 represents amino acids 89-99 and is within the putative binding site between amino acids 85 and 105. Peptide 1, which also lies within the amino acid 40-79 site, bound GST/p56 l~k poorly (relative to peptides 2 and 4) in two experiments (Fig. 8 A) or not at all in eight experiments (data not shown). Peptide 3 (which resides between amino acids 75 and 85) and peptide 5 (which resides between amino acids 98 and 108) failed to bind in every experiment (Fig. 8 A) . There also was no binding to a control peptide corresponding to a CD2 cytoplasmic sequence that was not rich in prolines (data not shown).
Because peptide 2 bound GST/p56 lck best, we determined the effect on binding of truncating this peptide. The following peptides were synthesized, immobilized on Sepharose, and assayed for their ability to bind GST/p561ck: HI<PLPPSHI(, PLPPSHI( and HI<PLPPS. Only H I ( P L P P S H I ( bound GST/p56 lck (Fig. 8 B) . This peptide differed from peptide 2 by the deletion of PG on the NH2 terminus. The removal of the HI< from either the NH2 terminus or the C O O H terminus resulted in loss of binding (Fig. 8 /3 ), suggesting either that the flanking basic amino acids are required for binding o f this peptide to the SH3 domain of p561ok or that the peptide length must exceed seven residues. Although our studies do not distinguish between these possibilities, the sequences o f the first and second proline-rich regions are quite similar, the major difference being that the second has basic amino acids at both flanks of the prolines, whereas the first has basic residues at the carboxy terminus only. The absence of NH2-terminal basic residues may explain the decreased ability of the peptide derived from the first proline-rich region (peptide 1) to bind GST/p56 lck.
The First Two Proline-rich Regions in the Cytoplasmic Tail of CD2 Are Not Required for Coupling to Signaling Pathways.
Previous studies examining the structural requirements for signal transduction by human CD2 indicated that the first two proline-rich regions in the cytoplasmic domain of human CD2 were required for signal transduction by CD2 (21, 36, 37) . Chang et al. (21) demonstrated that a truncation mutant retaining 77 amino acids, but not one retaining 43 amino acids, of the cytoplasmic domain o f human CD2 could couple to a rise in free intracellular calcium ([Ca>]i) and IL-2 production, suggesting that an essential sequence for human CD2 signal transduction lies between amino acids 43 and 77. Point mutations on either side of the second proline-rich domain did not affect IL-2 production, but a substitution of DE for the HI< after the first proline-rich region abrogated signaling, consistent with a key role of the first proline-rich region in CD2 signal transduction (37) . This finding could not be corroborated by Hahn and Bierer (36) , who found that the same H I ( to DE substitution failed to have an effect on CD2 signaling. They did note that deletion of either the first or second proline-rich region resulted in a reduction of CD2-mediated IL-2 production, and elimination of both regions completely abrogated CD2 signaling (36) . Therefore, although the studies differed on the relative importance o f the first and second proline-rich regions, both studies clearly defined this region as essential for CD2-mediated signaling.
Our CY78 mutant, which retains the first two prolinerich regions in the cytoplasmic domain of CD2, can bind p56 lck in vitro and, thus, is consistent with the notion that the binding o f p56 lck by CD2 is important in CD2-mediated signaling. O n the other hand, based on the earlier functional studies, our CY49.69 would not be expected to couple to signaling pathways even though we find that it binds p56 lck in vitro (36, 37) . Therefore, we investigated the possibility that CY49.69 could couple to signaling pathways in T cells. To this end, we expressed F.L. rat (a) Proline-rich peptides in the cytoplasmic domain of CD2 can bind p56 lck. l l-mer peptides corresponding to five prolinerich regions (1) (2) (3) (4) (5) in the cytoplasmic domain of CD2 were synthesized (peptide 4 is a 12-mer; a glycine was added to the NH2 terminus to prevent cyclization of the NH2-terminal glutamine). The locations and sequences of the peptides are indicated in the diagram. The peptides were coupled to Sepharose and used to precipitate pudried GST/p56 lck. (b) The effect of truncations on the ability ofpeptide 2 to bind p56 lck. Peptides indicated above the lanes in Fig. 8 b were synthesized, conjugated to Sepharose, incubated with equivalent concentrations of purified GST/p56 l'k, and immunoblotted with anti-GST antiserum. CD2 and the CY49.69 mutant in the human T cell line, Jurkat, and assessed the ability of each to couple to a rise in [Ca2+]i and to produce IL-2 after CD2 stimulation.
As previously described, F.L. CD2 can stimulate a rise in
[Ca2+]i when activated with a pair of anti-rat CD2 mAb (OX-54 and OX-55; Fig. 9 ). Similarly, the CY49.69 construct stimulated a rise in [Ca2+]i comparable to that seen with F.L. CD2 when activated with OX-54 and OX-55 (Fig. 9 ). To determine whether these constructs are capable of producing IL-2 in response to anti-CD2 stimulation, we stimulated F.L. CD2 Jurkat and CY49.69 with PMA alone, the combination of OX-54, OX-55, and PMA, or the combination of C305 (anti-TCR.) and PMA. As previously demonstrated, stimulation of F.L. rat CD2 results in IL-2 production comparable to that seen after TCP, stimulation (Table 1) . CY49.69 also produced IL-2 in response to CD2 stimulation, and the amount of IL-2 produced was comparable to that elicited by TCR. stimulation (Table 1 ). These data demonstrate that the first two proline-rich regions in the cytoplasmic tail of CD2 are not required for CD2 to transduce signals.
Discussion
In this report we have examined the mechanism by which CD2 and p56 kk associate. The interaction between these does not require the coexpression of other leukocytespecific molecules, as evidenced by the ability of CD2 and p56 kk to associate in COS cells and Sf9 cells. Therefore, although CD2 coprecipitates with a number of lineagerestricted molecules, including the TCR., CD4, CD45, and CD53, none of these need be present for CD2 to associate with p56 kk (11, t2). The association requires the cytoplasmic domain of CD2, to which the SH3 domain of p56 lck binds. Truncation mutants of CD2 reveal two regions whose deletion leads to a substantial decrease in the amount of p56 lck that coprecipitates with CD2. When the cytoplasmic domain is shortened from 105 to 85 amino acids, there is a 70% decrease in the amount of p56 kk binding, relative to full length CD2. As the cytoplasmic tail of CD2 is further shortened from 78 to 40 amino acids, virtually all binding to p56 lck is lost. Each of these regions contains a proline-rich sequence that, in the form of an immobilized, synthetic peptide, binds p56 kk. Thus proline-rich sequences, which are a distinctive feature of the CD2 cytoplasmic domain, allow this transmembrane receptor to couple to p56 lck by binding its SH3 domains.
SH3 domains, which are found primarily in enzymes and other molecules involved in signal transduction, mediate protein-protein interactions (38) . A striking feature of the known binding sites for SH3 domains is the frequency of proline residues (32) . The sequence requirements for interactions with the SH3 domains of most proteins, including p56 lck, are not known. Yu et al. (39) recently screened a 9-mer combinatorial peptide library in order to identify amino acid sequences that can bind the SH3 domain of p60 src. The library, which was in the form of XXXPPX-PXX, was biased to include a common PPXP motif. Two classes ofpeptides bound to the Src SH3 domain. All mem- 106 cells were stimulated overnight with PMA (10 ng/ml) alone, anti-rat CD2 mAb (25 mg/ml of OX-54 and OX-55) plus PMA, or anti-TCR mAb (1:500 dilution from C305 ascites) plus PMA. Culture supernatants were assayed for IL-2 as described in Materials and Methods. Data presented are representative of at least four independent experiments. At least two separate clones for each construct were evaluated.
bers of the first group had an R_XL motif at the amino terminus and a leucine at position 6; the majority had a basic amino acid, usually arginine, at the penultimate position and a hydrophobic amino acid at the carbox 3" terminus. Peptide 2 from the CD2 cytoplasmic domain also has an amino terminal RXL motif and an arginine at the equivalent of the penultimate position of the library peptide. In the CD2 sequence this arginine (which is the COOH terminus of peptide 2) is followed by a hydrophobic residue. Peptide 4 contains the motif PPLPR, which is the common feature of the second class of Src SH3 domain-binding peptides. Thus, both CD2 sequences that bind p56 kk share key features with peptides selected for their abili b-to bind to the SH3 domain of a closely related PTK, p60Srq In contrast, analysis of the other proline-rich sequences in CD2 fails to reveal similarities between these sequences and the Src SH3 domain-binding peptides.
By interacting with the SH3 domain of p56 kk, CD2 may influence the enzymatic activity of this PTK. Phosphorylation ofa COOH-ternfinal tyrosine residue (tyrosine 505 in p56 l~k) down regulates the activity of Src-like PTKs (40) . The phosphory, lated COOH-ternfinal tyrosine likely binds to the SH2 domain of the kinase, causing the PTK to fold back on itself and rendering the kinase inactive. It has been proposed that an interaction between the SH3 domain and a proline-rich region in the COOH terminus of p56 kk further stabilizes this "closed" conformation (41) . Indeed, nmtations in the SH3 domain of Src-like PTKs, which would prevent this interaction, increase kinase activity (40) . When p56 Ick binds to CD2, its SH3 domain is occupied, preventing it from interacting with the COOH-tem~inal prolinerich region of p56 I&. This may destabilize the inactive conformation of p56 lck and favor an "open" or active form of the kinase. It is possible, therefore, that there is an important qualitative difference between CD2-associated p56 kk and the p56 lck associated with receptors, such as CD4 or CD8, that, by interacting with the unique region of p56 kk, should not affect the stability of the inactive form of the enzyme (42, 43) .
Previous studies by several investigators have focused on the potential importance of proline-rich sequences for signaling by human CD2 (21, 36, 37) . Mutants with as few as the first 77 an-fino acids of the cytoplasnfic domain of human CD2 were capable of coupling to a rise in [Ca2+]i and IL-2 production, whereas truncations to ~<43 amino acids failed to couple to signaling pathways, suggesting that the region between amino acids 43 and 77 was required for CD2 signal transduction (21) . This region contains the first two proline-rich domains. Mutational analysis of this region has led to conflicting results. Chang et al. (37) found that substitution of the HR with DE af}er the first prolinerich region, but not the second, resulted in a loss of signaling by CD2. Alternatively, when Hahn and Bierer (36) made the same mutation, they failed to detect a change in IL-2 production after CD2 stimulation. Internal deletion mutants excising either of the PPPGHR, motifs in the first and second proline-rich regions reduced CD2-mediated IL-2 production, and deletion of this motif in both regions
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CD2 Association with p56 kk resulted in complete abrogation of CD2-mediated IL-2 production (36). Consistent with the findings presented above, an internal deletion lacking amino acids 19-77 of the cytoplasmic tail of human CD2 also failed to produce IL-2 in response to CD2 stimulation (36) .
In our experiments, deletion of the first and second proline-rich regions (CY49.69) had little if any effect on the ability of CD2 to couple to a rise in [Ca2+]i or to IL-2 production. Although the rat and human sequences differ slightly in the first two proline-rich regions, they are identical in the fourth and fifth proline-rich regions (amino acids 80-103 in the human), suggesting that a constrnct comparable to our CY49.69 in the hmnan would signal. The reason for the discrepancy between our results and those of Hahn and Bierer (36) may lie in the way the constructs were made. One of Hahn and Bierer's constructs retained the sequences between the proline-rich domains and the other excised a larger portion of the cytoplasmic domain than our CY49.69. This may have resulted in secondarystructural changes that prevented the fourth proline-rich region from binding p56 Ick.
Our studies indicate that specific proline-rich regions in the COOH-ternfinal half of the cytoplasmic domain of CD2 mediate the direct interactions of CD2 and p56 kk by binding the SH3 domain of p56 lck. Carmo et al. (13) , however, have shown that p56 lck is present in CD2 immunoprecipitates from the CY40 mutant expressed in Jurkat. These immunoprecipitations were performed using Brij 96 lysates. It is possible that the proximal 40 amino acids in the cytoplasmic domain of CD2 may associate with other molecules that mediate an association with p56 lck and that these associations are not maintained in the conditions we used for our studies (1% NP-40 lysis buffer). Our studies indicate that the first 40 amino acids do not participate in the direct binding to p56 lck. Neither our CY40 truncation nmtant nor our T7-40 fusion protein coprecipitated with GST/p56 kk. Additionally, our 7.41 internal deletion mutant, which lacks anfino acids 7-4l of the cytoplasnfic tail of CD2, consistently bound p56 kk better than F.L. CD2.
Because the CD2 sequences that bind the p56 kk SH3 domain resemble the consensus sequences for binding the p60 s~ SH3 domain, interactions between CD2 and the Src family may not be limited to p56 I~k but may involve other members as well. Several observations indicate that this is likely the case. Both p596'" and p56 kk coinmmnoprecipitate with CD2 fi'om T cells and NK cells, raising the possibility that p596" directly interacts with CD2 (13, 14, 27) . We also have fbund that another Src-like kinase, p54bn coimmunoprecipates with CD2 when the latter is expressed in I~I3L, a rat basophilic leukemia line that does not express p56 I& (G. Bell; unpublished observations). We are currently investigating whether the SH3 domains ofp596'" and p54 ly" mediate these interactions with CD2 and whether they bind the same CD2 sequences as p56 kk.
Although our results are consistent with a role for p56 l& in CD2-mediated signaling, we cannot conclude that the association with p56 k'k is sufficient or even necessary-for CD2 signaling. An interesting possibility, not addressed in our study, is that signaling molecules other than the Srclike PTKs interact with CD2 using a mechanism similar to the one described here. Of note in this regard, the peptide corresponding to the first proline-rich region (peptide 1) binds p56 l~k poorly and does not resemble the Src SH3 domain-binding peptides. Nevertheless, deletion of this region in human CD2 results in a 10-fold reduction of CD2-mediated IL-2 production (36). One possibility is that this proline-rich region binds to the SH3 domain of signaling molecule, other than a Src-like PTK, which may be required for CD2-mediated signal transduction.
CD2-mediated signaling requires the presence of the TCR or of receptors that contain members of the TCR chain family (16, 44) . Perturbation of CD2 on T cells leads to the tyrosine phosphorylation of the TCR.-/~ chain, and it is likely that this event is crucial for CD2 signaling (20, 26) . Tyrosine phosphorylation triggers an association between TC1K-~ and ZAP70, a PTK thought to play a critical role in TC1K signaling (45) . As noted above, CD2 appears to be in physical proximity with the TCR and, under certain conditions, TC1K-~ coimmunoprecipitates with CD2 (12) . The demonstration that CD2 associates with p56 lck suggests that, like the CD4 and CD8 coreceptors, CD2 may bring p56 kk into proximity with potential substrates within the TC1K complex. Furthermore, the mechanism by which CD2 associates with p56 kk may make CD2 uniquely suited to stimulate the phosphorylation of TCR components.
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